Ads
related to: anti-gd2 antibody- Dako CoverStainer
Automate H&E staining with
Dako CoverStainer.
- Special Stains Kits
High-quality RTU stain kits
enable consistent special stains.
- Dako Omnis
A fully automated IHC & ISH
platform for faster diagnosis.
- H&E Reagents
Explore our portfolio of
ready-to-use H&E reagents.
- Autostainer Link 48
Improve your workload management
with Agilent's IHC instrument.
- Request A Quote
Get in touch with an Agilent
representative today.
- Dako CoverStainer
Search results
Results From The WOW.Com Content Network
An example of such antibodies is hu14.18K322A, a monoclonal antibody. This anti-GD2 antibody is currently undergoing a phase II clinical trial in the treatment of previously untreated high risk neuroblastoma given alongside combination chemotherapy prior to stem cell transplant and radiation therapy . [ 2 ]
GD2 is a glycolipid that is expressed on the surface of neuroblastoma cells. [1] It is targeted through immunotherapy in neuroblastoma treatment using monoclonal antibodies. [1] These monoclonal antibodies are used to block GD2 expression, and are thus referred to as anti-GD2 agents.
Each antibody is made of both mouse and human components and targets glycolipid GD2, expressed on neuroblastoma cells and on normal cells of neuroectodermal origin, including the central nervous system and peripheral nerves. They differ in that dinutuximab is manufactured using mouse cells, and dinutuximab beta is manufactured using hamster cells.
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today reported financial results ...
Anti-GD1a antibodies were highly associated acute motor axonal neuropathy while high titers of anti-GM1 were more frequent indicating that GD1a possibly targets the axolemma and nodes of Ranvier [3] most of the Ab+ patients had C. jejuni infections. Patients with Anti-GalNAc-GD1a antibodies were less common but had more severe disease (rapidly ...
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.